Sarepta price target lowered to $141 from $193 at Barclays

Barclays lowered the firm’s price target on Sarepta to $141 from $193 and keeps an Overweight rating on the shares post the Q3 report. Sarepta reported a strong initial Elevidys launch with an incremental update on the regulatory path post EMBARK data release, the analyst tells investors in a research note. The firm expects a continued strong Elevidys launch in 4-5 year old patients, with limited risk of withdrawal from the market.